Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: A prospective study

Amyloid

Volumn 21, Issue 4, 2014, Pages 246-255

  Deux, Jean François ^a   Damy, Thibaud ^a   Rahmouni, Alain ^a   Mayer, Julie ^a   Planté Bordeneuve, Violaine ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Amyloid; Cardiac; Magnetic resonance imaging; Transthyretin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GADOTERATE MEGLUMINE; METHIONINE; VALINE;

ADULT; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; FEMALE; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEREDITARY TRANSTHYRETIN ASSOCIATED AMYLOIDOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE SCANNER; PHENOTYPE; PROSPECTIVE STUDY; AGED; FAMILIAL AMYLOID POLYNEUROPATHY; GENETICS; HEART; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; FEMALE; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84908545188     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2014.956924     Document Type: Article

References (28)

1. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart 2012;98:1546-54.
2. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
3. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 2011;124:1079-85.
4. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
5. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107:2446-52.
6. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 2014;129:1840-9.
7. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-15.
8. Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 2014;21:271-83.
9. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
10. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009;103:544-9.
11. Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N. Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging 2009;30:942-6.
12. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-64.
13. Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009;2:1369-77.
14. Di Bella G, Minutoli F, Mazzeo A, Vita G, Oreto G, Carerj S, Anfuso C, et al. MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol 2010;195: W394-9.
15. Minutoli F, Di Bella G, Mazzeo A, Donato R, Russo M, Scribano E, Baldari S. Comparison between 99mTc-diphosphonate imaging and mri with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid poly-neuropathy. AJR Am J Roentgenol 2013;200:W256-65.
16. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92:343-9.
17. Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 2013;20:212-20.
18. Benson L, Hemmingsson A, Ericsson A, Jung B, Sperber G, Thuomas KA, Westermark P. Magnetic resonance imaging in primary amyloidosis. Acta Radiol 1987;28:13-15.
19. Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998;136:824-30.
20. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
21. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10:54.
22. Baccouche H, Maunz M, Beck T, Gaa E, Banzhaf M, Knayer U, Fogarassy P, et al. Differentiating cardiac amyloidosis and hyper-trophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012;29:668-77.
23. Leone O, Longhi S, Quarta CC, Ragazzini T, De Giorgi LB, Pasquale F, Potena L, et al. New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid 2012;19:99-105.
24. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51: 1022-30.
25. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Janet AG, Lachmann HJ, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014;7: 133-42.
26. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8.
27. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012;83:152-8.
28. Fontana M, Banypersad MC, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, et al. Native T1 mapping in Transthyretin Amyloidosis. JACC Cardiovasc Imaging 2014; 7: 157-65.